The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top ...

Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as ...

Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences Limited and Takeda ...

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...